Triptych case soy broth γ-ray irradiated (Japanese Pharmacopoeia medium filling test)
This is a medium for the "Medium Filling Test (Process Simulation)" of the 16th edition of the Japanese Pharmacopoeia, and it can be used simply by dissolving it in sterilized water.
BD BBL Trypticase Soy Broth γ-ray irradiated is a medium for the "Medium Filling Test (Process Simulation)" listed in the 16th edition of the Japanese Pharmacopoeia, and it can be used simply by dissolving it in sterilized water. It is a γ-ray irradiated Trypticase Soy Broth formulated in accordance with the tripartite pharmacopoeia, designed for use in pharmaceutical manufacturing area environmental monitoring with minimal risk of microbiological contamination to the environment. Quality and performance tests compliant with the pharmacopoeia are conducted, and a Certificate of Analysis is issued for each lot in accordance with these tests.
basic information
Composition (per 1L of purified water) Casein peptone ............................ 17.0 g Soy peptone ................................ 3.0 g Sodium chloride ........................... 5.0 g Potassium hydrogen phosphate .......... 2.5 g Glucose ..................................... 2.5 g pH 7.1 ± 0.2
Price range
P2
Delivery Time
P2
Applications/Examples of results
This is a medium for the "Medium Filling Test (Process Simulation)" of the 16th edition of the Japanese Pharmacopoeia, and it can be used simply by dissolving it in sterilized water.
Line up（1）
| Model number | overview |
|---|---|
| 296264 | BD BBL Triptych Case Soybros γ Irradiated |
Recommended products
Distributors
BD Japan is the Japanese subsidiary of BD, one of the world's leading medical device and medtech companies headquartered in New Jersey, USA. BD aims to lead the world in medical technology, seeking new insights in the healthcare field and improving the quality of diagnosis and treatment, with the purpose of realizing "The future of healthcare for all(TM)." By developing innovative technologies and services related to patient treatment and healthcare processes, BD supports those working on the front lines of healthcare. With approximately 77,000 employees worldwide, BD staff support researchers in the development of next-generation diagnostic and therapeutic methods and strive daily to enhance the safety of healthcare professionals and the efficiency of medical practices in clinical settings. By partnering with healthcare institutions in countries around the world and addressing global priority issues, BD contributes to improving healthcare outcomes, reducing costs, increasing efficiency, enhancing safety, and promoting access to healthcare through close collaboration with its customers, the healthcare institutions.